David Dornan - 15 Feb 2023 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)

Role
CHIEF SCIENTIFIC OFFICER
Signature
/s/ Robert Yang, Attorney-in-Fact
Issuer symbol
ELEV
Transactions as of
15 Feb 2023
Net transactions value
$0
Form type
4
Filing time
17 Feb 2023, 15:26:45 UTC
Previous filing
10 Jan 2023
Next filing
20 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELEV Stock Option (Right to Buy) Award $0 +130,000 $0.000000 130,000 15 Feb 2023 Common Stock 130,000 $0.9800 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 25% of the total shares on February 15, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.